Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

COVID-19 mRNA vaccines create enough of an immunity boost to extend survival in certain types of lung and skin cancers, an analysis of more than 1,000 patient files showed. The scientific journal ...

Moderna’s latest clinical update centers on a long‑term extension of its cytomegalovirus (CMV) vaccine program, officially titled “A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

LANSING, Mich. (WLNS) — Canceling federal mRNA vaccine projects threatens much more than pandemic response, according to Michigan State University’s Director of the Precision Health Program Anna Moore ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...

Moderna MRNA announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in funding to support a pivotal phase III study evaluating its investigational ...